Skip to Main content Skip to Navigation
Journal articles

12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation

Abstract : Sofosbuvir (SOF) combined with NS5A inhibitors has demonstrated its efficacy in treating a recurrence of HCV after liver transplantation. However, the duration of treatment and the need for ribavirin (RBV) remain unclear in this population. Our aim was to determine whether liver transplant recipients could be treated with an SOF+NS5A inhibitor-based regimen without RBV for 12 weeks after liver transplantation (LT).
Document type :
Journal articles
Complete list of metadatas

https://hal-univ-rennes1.archives-ouvertes.fr/hal-01807755
Contributor : Laurent Jonchère <>
Submitted on : Tuesday, June 5, 2018 - 10:25:47 AM
Last modification on : Tuesday, October 27, 2020 - 2:34:43 PM

Links full text

Identifiers

Citation

Pauline Houssel-Debry, Audrey Coilly, Claire Fougerou-Leurent, Caroline Jezequel, Christophe Duvoux, et al.. 12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation. Hepatology, Wiley-Blackwell, 2018, 68 (4), pp.1277-1287. ⟨10.1002/hep.29918⟩. ⟨hal-01807755⟩

Share

Metrics

Record views

399